Evaluation of Direct-acting Antiviral Agents and Clinical Responses in Chronic Hepatitis C Patients

Direct-acting Antiviral Agents Responses ABSTRACT Objectives: Direct-acting antiviral (DAA) agents have made a breakthrough for treating chronic hepatitis C virus (HCV) with their high efficacy and tolerability. In this study, the end of treatment response of DAA treatment regimens was analyzed with respect to epidemiological data. Materials and Methods: A total of 143 patients, over 18 years of age, who were treated with the diagnosis of HCV infection were analyzed retrospectively. The comorbid diseases, co-infection status (hepatitis B virus and human immunodeficiency virus-co-infection), genotype distribution and transmission routes were noted. The changes in the laboratory parameters were evaluated before treatment, at the first month and at the end of treatment and after treatment at the 12 th week. Results: When the genotype distributions of the patients were examined, it was found that 75.5% of the patients (n=108) were genotype-1, 4.2% (n=6) were genotype-2, 12.6% (n=18) were genotype-3, 4.9% (n=7) were genotype-4, and 1.4% (n=2) were genotype-5. The treatment regimens of the patients were; paritaprevir + ritonavir + ombitasvir + dasabuvir in 54 (37.8%) patients, ledipasvir + sofosbuvir in 28 (19.6%) patients, glecaprevir + pibrentasvir in 23 (16.1%) patients, and paritaprevir + ritonavir + ombitasvir + dasabuvir + ribavirin (RBV) in 15 (10.5%) patients. Dose reduction was implemented in 31 patients who received RBV treatment. Adverse events were observed in 49.7% (n=71) n of the study population. The rate of sustained viral response-12 (SVR12) was 100% in all treatment regimens. Conclusion: Achieving a SVR12 in chronic HCV decreased all-cause mortality, whether liver-related or unrelated. Second-generation DAAs have been a beacon of hope for humanity in this regard.